GW Pharmaceuticals PLC Notice of Results (8405G)
November 24 2015 - 12:00PM
UK Regulatory
TIDMGWP
RNS Number : 8405G
GW Pharmaceuticals PLC
24 November 2015
GW Pharmaceuticals to Report Q4 and Year-End 2015 Financial
Results and Host Conference Call on 3 December, 2015
London, UK, 24 Nov 2015: GW Pharmaceuticals plc (Nasdaq: GWPH,
AIM: GWP, "GW" or "the Company"), a biopharmaceutical company
focused on discovering, developing and commercializing novel
therapeutics from its proprietary cannabinoid product platform,
will announce on 3 December, 2015 its fourth quarter and year-end
financial results for the period ending 30 September, 2015. GW will
also host a conference call the same day at 8:00 a.m. EST (1:00
p.m. GMT). Conference call information will be provided in the
financial results press release. A replay of the call will also be
available through the Company's website (www.gwpharm.com) shortly
after the call.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex(R) , which is approved for
the treatment of spasticity due to multiple sclerosis in 27
countries outside the United States. GW is advancing an orphan drug
program in the field of childhood epilepsy with a focus on
Epidiolex(R) , which is in Phase 3 clinical development for the
treatment of Dravet syndrome and Lennox-Gastaut syndrome and which
is also expected to enter Phase 3 clinical trials in the treatment
of Tuberous Sclerosis Complex. GW has a deep pipeline of additional
cannabinoid product candidates which includes Sativex in Phase 3
clinical development as a potential treatment of pain associated
with advanced cancer, as well as compounds in Phase 1 and 2 trials
for glioma, type 2 diabetes, and schizophrenia. For further
information, please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc (Today) +44 20 3727 1000
Stephen Schultz, VP Investor Relations
(U.S.) 917 280 2424 / 401 500 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway + 44 20 3727 1000
Peel Hunt LLP (UK NOMAD)
James Steel +44 20 7418 8900
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORDZLFLEFFBFBK
(END) Dow Jones Newswires
November 24, 2015 13:00 ET (18:00 GMT)
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about GW Pharm. (London Stock Exchange): 0 recent articles
More GW Pharm. News Articles